Pixium Vision Postpones Decision on Takeover Offer

Pixium Vision has announced a delay in the Paris Commercial Court's decision regarding the takeover offer filed on November 20, 2023, and the initiation of judicial liquidation proceedings.

The company will communicate the rescheduled date as soon as it becomes available. Investors are urged to note that, considering the price proposed by the potential buyer and Pixium's existing level of indebtedness, the anticipated sale proceeds, even in the event of a favorable decision by the Commercial Court, will not be sufficient for a complete or partial reimbursement of shareholders.

Pixium Vision, known for developing bionic vision systems, focuses on restoring visual perception and autonomy for those who have experienced sight loss. The Prima System, a sub-retinal miniature photovoltaic wireless implant, is currently undergoing clinical testing for patients affected by outer retinal degeneration, initially targeting atrophic dry age-related macular degeneration (AMD).

The company remains committed to advancing innovative solutions despite the current financial considerations.